📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial. (2025)

First Author: Heinrich N

Attributed to: Respiratory infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.lanmic.2024.07.015

PubMed Identifier: 39793592

Publication URI: http://europepmc.org/abstract/MED/39793592

Type: Journal Article/Review

Volume: 6

Parent Publication: The Lancet. Microbe

Issue: 2

ISSN: 2666-5247